Abstract
Does the oncotype DX assay recurrence score correlate with other predictive tools when planning adjuvant chemotherapy in early breast cancer?
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International journal of surgery (London, England)
Paper Title
Journal
Date
